23314-57-0

Usage

Uses

Used in Pharmaceutical Applications:
Triarachidonin is used as a bioactive compound for stimulating prostaglandin synthesis in the kidney in a dose-dependent manner. This makes it a potential candidate for the development of pharmaceuticals targeting kidney-related conditions.
Used in Diabetes Management:
Triarachidonin is used as a therapeutic agent for inhibiting the hepatic stearoyl-CoA desaturase-1 gene in diabetic mice. This application suggests its potential use in the development of treatments for diabetes and related metabolic disorders.

InChI:InChI=1/C63H98O6/c1-4-7-10-13-16-19-22-25-28-31-34-37-40-43-46-49-52-55-61(64)67-58-60(69-63(66)57-54-51-48-45-42-39-36-33-30-27-24-21-18-15-12-9-6-3)59-68-62(65)56-53-50-47-44-41-38-35-32-29-26-23-20-17-14-11-8-5-2/h16-21,25-30,34-39,43-48,60H,4-15,22-24,31-33,40-42,49-59H2,1-3H3/b19-16+,20-17+,21-18+,28-25+,29-26+,30-27+,37-34+,38-35+,39-36+,46-43+,47-44+,48-45+

Upstream product

• 506-32-1 all cis 5,8,11,14-eicosatetraenoic acid 
• 56-81-5 glycerol 
• 57303-04-5 arachidonoyl chloride 

Relevant academic research and scientific papers

TREATMENT OF NEURODEGENERATIVE CONDITIONS

A method is provided for treating a patient in need of therapy for a neurodegenerative disease comprising administering to that patient a therapeutically effective dose of a lipid glyceride comprising a glycerol moiety and a fatty acid moiety, the fatty acid moiety being selected from the group consisting of γ-linolenic acid, dihomo-γ-linolenic acid and arachidonic acid characterised in that the selected fatty acid moiety is attached to the glycerol moiety at its sn-2 position. Preferably the method is that wherein the lipid is administered for a duration and at a dose sufficient to maintain or elevate TGF-β1 levels in the patient to therapeutic levels.

Synthesis of Triacylglycerol from Polyunsaturated Fatty Acid by Immobilized Lipase

More than 95percent of polyunsaturated acid (PUFA) was converted to triacylglycerol by immobilized lipase from Candida antarctica or Rhizomucor miehei.The esterification was carried out at 50-60 deg C with shaking and dehydration for 24 h.The substrates consisted of glycerol and free fatty acid or ethyl esters of the fatty acid at a 1:3 molar ratio.The docosahexaenoic acid (DHA) or eicosapentaenoic acid (EPA) in the substrate polymerized during the reaction, and they required 5-10percent more than the stoichiometric amount to compensate for the PUFA loss.On the contrary, ethyl esters of DHA and EPA were not polymerized.Pure tridocosahexaenoyl, trieicosapentaenoyl and triarachidonoyl glycerol were isolated after passing the product through a basic aluminum oxide column.Industrial feasibility of this process was discussed for the ethyl ester as substrate. KEY WORDS: Docosahexaenoic acid, docosahexaenoyl ethyl ester, eicosapentaenoic acid, immobilized lipase, lipase, polyunsaturated fatty acid, triacylglycerol, triarachidonoyl glycerol, tridocosahexaenoyl glycerol, trieicosapentaenoyl glycerol.